Approaches to optimize the use of monoclonal antibodies to epidermal growth factor receptor

Area of Science:

• Oncology
• Immunotherapy
• Molecular Biology

Background:

• Monoclonal antibodies (mAbs) targeting the epidermal growth factor receptor (EGFR) exhibit antitumor activity.
• EGFR is frequently dysregulated in human cancers, particularly carcinomas.
• The clinical efficacy of current anti-EGFR mAbs is often suboptimal relative to EGFR's prevalence in malignancies.

Purpose of the Study:

• To review current strategies aimed at enhancing the therapeutic efficacy of anti-EGFR monoclonal antibodies.
• To explore technological and clinical advancements for optimizing anti-EGFR antibody treatments.

Main Methods:

• Review of preclinical and clinical studies on anti-EGFR monoclonal antibodies.
• Analysis of approaches including antibody humanization, conjugation, specificity widening, and combination therapies.
• Evaluation of methods to improve the therapeutic index of these agents.

Main Results:

• Various approaches are under investigation to boost the potency of EGFR-targeting mAbs.
• Optimizing antibody characteristics and combining therapies show potential for increased antitumor activity.
• Current research focuses on overcoming limitations to achieve better clinical outcomes.

Conclusions:

• Enhancing anti-EGFR monoclonal antibody therapy is crucial for improving cancer treatment.
• Technological innovations and strategic combinations hold promise for greater therapeutic success.
• Further research into optimizing these agents is essential for maximizing their clinical benefit.